Coya Therapeutics, Inc.
COYANasdaq
$4.54
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↓ -21.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$102.8M
Enterprise Value
$52.1M
P/E
—
P/S
12.9
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$7.9M
Net Income (TTM)
-$21.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-283.6%
Net Margin
-266.1%
ROE
-43.1%
ROIC
—
Debt / Equity
—
Net Cash
$50.7M
Return 1Y
-23.8%
Company profile
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We were incorporated under the laws of the state of Delaware on November 23, 2020 under the name Coya Therapeutics, Inc. On December 22, 2020, we consummated the Corporate Reorganization pursuant to which all of the issued and outstanding stock of Nicoya Health, Inc., a Delaware corporation formed in 2020, were exchanged for common stock of Coya Therapeutics, Inc. Our principal executive offices are located at 5850 San Felipe St, Suite 500, Houston, TX.
- CEO
- Howard Berman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 6
- Headquarters
- Texas
- Website
- coyatherapeutics.com
Earnings
COYA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$251,147.00↓ -2.6%
Diluted EPS-$0.32↓ -27.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $0.00 | $6.0M | $3.6M | $7.9M |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.9M | -$9.8M | -$7.9M | -$17.2M | -$22.6M |
| Net income | -$4.9M | -$12.2M | -$8.0M | -$14.9M | -$21.2M |
| Diluted EPS | -$1.89 | -$4.73 | -$0.79 | -$0.98 | -$1.27 |
| Operating cash flow | -$3.9M | -$7.2M | -$11.2M | -$10.3M | -$10.7M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | -131.7% | -485.4% | -283.9% |
| Net margin | — | — | -133.1% | -418.7% | -267.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $0.00 | $1,952.00 | $257,884.00 | $163,616.00 | $3.6M | $4.0M | $251,147.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.2M | -$4.5M | -$4.1M | -$7.7M | -$6.4M | -$2.4M | -$6.0M | -$7.6M |
| Net income | -$2.9M | -$4.0M | -$2.9M | -$7.3M | -$6.1M | -$2.1M | -$5.7M | -$7.2M |
| Diluted EPS | -$0.19 | -$0.26 | -$0.18 | -$0.44 | -$0.36 | -$0.13 | -$0.34 | -$0.32 |
| Operating cash flow | -$4.6M | -$5.5M | -$2.4M | -$2.8M | -$5.8M | -$1.1M | -$1.0M | -$6.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -94.5% | — | -209031.5% | -2976.9% | -3920.5% | -68.3% | -152.3% | -3042.1% |
| Net margin | -84.4% | — | -149373.8% | -2833.4% | -3725.2% | -59.4% | -144.2% | -2869.6% |
Company news
Jun 30, 2026
Jun 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-18 | GOLDSTEIN DOV A MD | Option exercise | 17,557 | $1.09 | $19,137.13 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.